Remove Events Remove Licensing Remove Treatment
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drugs 130
article thumbnail

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

Neuropsychiatric treatment is on the verge of a major transformation. Historically, treatment options have been limited, with patients relying on daily medications that have minimal efficacy and troublesome side effects. “We call this phenomenon ‘event-driven pharmacology.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The rise of GLP-1 drugs: Transforming weight loss treatment

BioPharma Drive: Drug Pricing

This shift raises ethical questions around prioritizing supply for diabetes patients versus those seeking treatment for obesity or cosmetic weight loss. You can unsubscribe at anytime. The balance is complex, as obesity carries its own serious health risks. TechTarget, Inc.s registered office is 275 Grove St. Newton, MA 02466.

Treatment 130
article thumbnail

Fitusiran

New Drug Approvals

1] [2] Adverse effects The US Food and Drug Administration prescription label for fitusiran contains a boxed warning for thrombotic events (blood clotting) and gallbladder disease (with some recipients requiring gallbladder removal). [2] Fitusiran 1711.0g/mol, 1] It is an antithrombin-directed small interfering ribonucleic acid. [1]

article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

The data, which encompass up to 3 years of follow-up after a single infusion of the treatment, were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held from June 13–16 in Glasgow, United Kingdom. President and Chief Executive Officer of Intellia Therapeutics.

article thumbnail

Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

The Pharma Data

Specifically, the trial measured the percentage of participants who achieved a ≥3-line gain in Early Treatment Diabetic Retinopathy Study (ETDRS) chart readings at 12 hours post-dose on Day 8, while maintaining less than a 5-letter loss in BCDVA from baseline.

Trials 40
article thumbnail

Biogen Launches Phase 3 Trial of Felzartamab for Primary Membranous Nephropathy

The Pharma Data

Despite its impact, there are currently no FDA-approved therapies for PMN , and treatment options are limited to non-specific and often toxic agents such as chemotherapy or general immunosuppressants. The rights to felzartamab were licensed to Human Immunology Biosciences (HI-Bio) , which Biogen acquired in July 2024. Source link

Trials 40